SCHEMBL4760580

SCHEMBL4760580

O=C(O)c1cc(S(=O)(=O)N2CCCC2)c(Cl)cc1Cl

nearest known ligand 0.97

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.97
KMT2A Q03164 3/20 0.97
ALDH1A1 P00352 3/20 0.97
LMNA P02545 2/20 0.97
TDP1 Q9NUW8 2/20 0.73
TSHR P16473 3/20 0.60
SMN1; SMN2 Q16637 1/20 0.59
CA12 O43570 1/20 0.58
CA1 P00915 1/20 0.58
CA2 P00918 1/20 0.58
CA3 P07451 1/20 0.58
CA4 P22748 1/20 0.58
CA6 P23280 1/20 0.58
CA5A P35218 1/20 0.58
CA7 P43166 1/20 0.58
CA9 Q16790 1/20 0.58
CA13 Q8N1Q1 1/20 0.58
CISD1 Q9NZ45 1/20 0.58
CA14 Q9ULX7 1/20 0.58
CA5B Q9Y2D0 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4716285 0.98 MEN1 (1.00) MEN1KMT2AALDH1A1LMNATDP1
SCHEMBL4716208 0.98 MEN1 (1.00) MEN1KMT2AALDH1A1LMNATDP1
SCHEMBL4761472 0.97 MEN1 (0.91) MEN1KMT2AALDH1A1LMNATDP1
SCHEMBL15733981 0.88 MEN1 (0.76) MEN1KMT2AALDH1A1LMNATDP1
SCHEMBL4760475 0.86 LMNA (0.74) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL19683494 0.86 KMT2A (0.74) MEN1KMT2AALDH1A1LMNATDP1
SCHEMBL12674484 0.86 MEN1 (0.74) MEN1KMT2AALDH1A1LMNATDP1
SCHEMBL4714278 0.86 KMT2A (0.74) MEN1KMT2AALDH1A1LMNATDP1
SCHEMBL12675015 0.85 MEN1 (0.72) MEN1KMT2AALDH1A1LMNATDP1
SCHEMBL11173490 0.85 MEN1 (0.76) MEN1KMT2AALDH1A1LMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615904-B1 SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS ASTRAZENECA AB (SE) 2008-02-27 EP disclosed
US-20070021606-A1 Therapeutic compounds ASTRAZENECA AB (SE) 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021606-A1 Therapeutic compounds GRIN1, GRIN3A, GRM2 MEN1 4633/4885KMT2A 3726/4885ALDH1A1 1721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.